Abstract
Effects of pancopride (5 and 10 mg, intravenously), on lower oesophageal sphincter pressure (LOESP), were assessed in healthy volunteers by means of oesophageal manometry. After pancopride 10 mg, the LOESP was higher than placebo and 5 mg pancopride but there were no differences among the three treatments (P = 0.42). The areas under the curve were similar without differences, neither with absolute measurements (P = 0.53) nor after a baseline correction (P = 0.16). In conclusion, pancopride has no clinically relevant effect on lower oesophageal sphincter pressure.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Clarke D. E., Craig D. A., Fozard J. R. The 5-HT4 receptor: naughty, but nice. Trends Pharmacol Sci. 1989 Oct;10(10):385–386. doi: 10.1016/0165-6147(89)90177-6. [DOI] [PubMed] [Google Scholar]
- Dodds W. J., Hogan W. J., Helm J. F., Dent J. Pathogenesis of reflux esophagitis. Gastroenterology. 1981 Aug;81(2):376–394. [PubMed] [Google Scholar]
- Dumuis A., Sebben M., Bockaert J. The gastrointestinal prokinetic benzamide derivatives are agonists at the non-classical 5-HT receptor (5-HT4) positively coupled to adenylate cyclase in neurons. Naunyn Schmiedebergs Arch Pharmacol. 1989 Oct;340(4):403–410. doi: 10.1007/BF00167041. [DOI] [PubMed] [Google Scholar]
- Fernández A. G., Puig J., Beleta J., Doménech T., Bou J., Berga P., Gristwood R. W., Roberts D. J. Pancopride, a potent and long-acting 5-HT3 receptor antagonist, is orally effective against anticancer drug-evoked emesis. Eur J Pharmacol. 1992 Nov 10;222(2-3):257–264. doi: 10.1016/0014-2999(92)90864-z. [DOI] [PubMed] [Google Scholar]
- Grande L., Lacima G., Ros E., Pujol A., Garcia-Valdecasas J. C., Fuster J., Visa J., Pera C. Dysphagia and esophageal motor dysfunction in gastroesophageal reflux are corrected by fundoplication. J Clin Gastroenterol. 1991 Feb;13(1):11–16. doi: 10.1097/00004836-199102000-00005. [DOI] [PubMed] [Google Scholar]
- Gullikson G. W., Loeffler R. F., Viriña M. A. Relationship of serotonin-3 receptor antagonist activity to gastric emptying and motor-stimulating actions of prokinetic drugs in dogs. J Pharmacol Exp Ther. 1991 Jul 1;258(1):103–110. [PubMed] [Google Scholar]
- Stacher G., Bergmann H., Granser-Vacariu G. V., Wiesnagrotzki S., Wenzelabatzi T. A., Gaupmann G., Kugi A., Steinringer H., Schneider C., Höbart J. Lack of systematic effects of the 5-hydroxytryptamine 3 receptor antagonist ICS 205-930 on gastric emptying and antral motor activity in patients with primary anorexia nervosa. Br J Clin Pharmacol. 1991 Dec;32(6):685–689. [PMC free article] [PubMed] [Google Scholar]
- Stacher G., Steiner G., Guapmann G., Stacher-Janotta G., Schneider C., Steinringer H. Effects of the 5-HT3 receptor antagonist, ICS 205-930, on oesophageal motor activity and on lower oesophageal sphincter pressure: a double-blind cross-over study. Hepatogastroenterology. 1990 Dec;37 (Suppl 2):118–121. [PubMed] [Google Scholar]
- Talley N. J. Review article: 5-hydroxytryptamine agonists and antagonists in the modulation of gastrointestinal motility and sensation: clinical implications. Aliment Pharmacol Ther. 1992 Jun;6(3):273–289. doi: 10.1111/j.1365-2036.1992.tb00050.x. [DOI] [PubMed] [Google Scholar]